Improved Sanofi HIV test approved in US:
This article was originally published in Clinica
Sanofi Diagnostics Pasteur has received FDA approval for a more sensitive and specific version of its HIV-1/HIV-2 Peptide enzyme immunoassay. The broad reactivity of the test is achieved by combining the most immunodominant synthetic peptide epitopes derived from the env and pol gene products for both HIV-1 and HIV-2, according to the company. Sanofi's US subsidiary, Genetic Systems, developed the new test and is marketing the product to US blood banks and other institutions.
You may also be interested in...
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.